BioMarin Pharmaceutical (BMRN) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-2.61 earnings per share for the quarter, missing the analyst consensus estimate by $-2.52. Analysts had a consensus of $-0.09. The company posted revenue of $300.10 million in the period, compared to analysts expectations of $279.05 million. The company’s revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.
BioMarin Pharmaceutical closed down -1.18 points or -1.18% at $99.07 with 19,26,746 shares getting traded on Tusday. Post opening the session at $99.96, the shares hit an intraday low of $97.4 and an intraday high of $100.9 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Aug 3, 2016, Daniel K Spiegelman (EVP, Chief Financial Officer) sold 4,000 shares at $99.33 per share price. According to the SEC, on Aug 3, 2016, George Eric Davis (EVP, General Counsel) sold 2,167 shares at $100.00 per share price. On Aug 3, 2016, Brian Mueller (VP, Corporate Controller) sold 287 shares at $100.00 per share price, according to the Form-4 filing with the securities and exchange commission.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).